Weight-loss supplement recalled after FDA finds undeclared toxic substance

Summary

Lipofit Extreme Fat Burner 2.0 is recalled due to undeclared fluoxetine and DNP. DNP is a toxic substance used as a pesticide, not approved for human consumption, and can cause severe health issues, including death. The FDA previously warned against purchasing this supplement.

Key Takeaways

1. A weight loss supplement has been recalled over two undeclared ingredients, including a toxic substance commonly used as a pesticide and herbicide.
2. The recall was initiated after an analysis by the Food and Drug Administration revealed the supplement was "tainted with undeclared fluoxetine in the daytime (AM) tablets and undeclared 2,4-dinitrophenol (DNP) in the nighttime (PM) tablets."
3. The FDA has described DNP as extremely dangerous and not fit for human consumption.

Statement Breakdown

• Claimed Facts: 70% of statements the article presents as facts
• Opinions: 20% of statements classified as editorial or subjective
• Claims: 10% of statements surfaced for additional reader evaluation

Credibility & Bias Reasoning

Credibility assessment: The article relies on official statements from the FDA and the company issuing the recall. It presents factual information about the recalled product and its ingredients. However, it lacks independent verification or expert commentary beyond what is attributed to the FDA.

Bias assessment: Consumer Safety Advocate. The article prioritizes reporting on product safety issues and recalls, highlighting potential dangers to consumers. It focuses on regulatory actions and warnings, framing the narrative around protecting public health from unsafe products.

Note: This article reports on a product recall based on FDA findings. While factual, it emphasizes potential dangers and regulatory actions, so consider this perspective when evaluating the information.

Credibility flag: Caution Advised

Claimed Facts (10)

• This states a verifiable action taken by a specific company.
• This provides specific identifying details for the recalled product.
• This attributes the findings to a specific regulatory body, the FDA.
• This states a fact about the approved uses of fluoxetine.
• This provides factual information about DNP's status and use.
• This lists the common industrial uses of DNP.
• This is a direct statement from the company regarding the product's regulatory status.
• This cites a specific study and its findings regarding DNP.
• This provides historical context for the regulation of DNP.
• This is a direct statement from the FDA about the danger of DNP.

Opinions (4)

• This statement outlines potential severe health consequences, presented as possibilities rather than guaranteed outcomes.
• This lists further potential adverse effects, framed as possibilities.
• This describes potential physiological responses that are presented as possible outcomes.
• This suggests a potential increased risk based on interactions, which is a predictive statement.

Claims (2)

• While good advice, this is a recommendation rather than a factual claim about the product itself.
• This is an instruction or directive, not a factual statement about the product's properties or effects.

Key Sources

• Landon Mion — Author
• Ana Salazar Modela Tu Cuerpo Inc. — Company
• Food and Drug Administration — Regulatory Agency
• U.K. medical researchers — Researchers